Aggrenox®

PRoFESS® - Study overview

Study design:
  • Randomised, double-blind, placebo-controlled multicentre study
Population:
  • 20,332 stroke patients
  • 695 stroke units in 35 countries
Treatment:
  • Aggrenox® vs. clopidogrel
  • The second study arm tested telmisartan versus placebo in addition to Aggrenox® or clopidogrel
Early treatment with Aggrenox®:
  • 40 % within the first 10 days
Treatment period:
  • 1.5 up to 4-4 years (median:2.5 years)
Primary outcome:
  • Time to recurrent stroke
Secondary outcome:
  • Stroke, myocardial infarction or vascular death

PRoFESS®: A global study that gives global insights into a representative patient population (20,332 patients)

PRoFESS® directly compares Aggrenox® and clopidogrel in secondary stroke prevention

References

Diener, Sacco, Yusuf. Cerebrovasc Dis 2007; 23: 368–380
PubMed Abstract

previous 1|2|3|4|5 next